Skip to search formSkip to main contentSkip to account menu

DCC-2036

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The receptor tyrosine kinase inhibitor, Tie2, has significant roles in endothelial signaling and angiogenesis, and is relevant in… 
2019
2019
TPS2666 Background: Rebastinib is a potent, orally administered, kinase switch control inhibitor selectively targeting the tunica… 
2013
2013
The paradigm-shifting clinical success of imatinib in the treatment of chronic myeloid leukemia (CML) established continuous… 
2012
2012
In some types of tumors, malignant cells are highly dependent on the constitutive activation of a certain protein encoded by… 
2012
2012
Th e introduction in clinical practice of tyrosine kinase inhibitors (TKIs) targeting the oncogenic BCR – ABL protein has had a… 
Review
2011
Review
2011
The 21st century ushered in the dawn of a new era of targeted therapeutics and a dramatic shift in the management of chronic… 
2011
2011
Abstract 601 Background. DCC-2036 is a novel and potent tyrosine kinase inhibitor (TKI) which binds to a novel region called the… 
2010
2010
Abstract 3398 Chronic Myeloid Leukemia (CML) treatment was radically modified by the discovery of imatinib (IM), a selective… 
Review
2010
Review
2010
Abstract 1226 Background: Mutations in the kinase domain (KD) of Abl represent the most common mechanism of resistance to… 
2007
2007
Therapy with ATP-competitive ABL kinase inhibitors, including imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna…